Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Associated Therapies: -

Clinical Trials

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer With EGFR-Activating Mutations

Interventions: Drug: Dacomitinib (PF-00299804)
Drug: Gefitinib

First Posted Date: 2013-01-24

Last Posted Date: 2023-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 452

Registration Number: NCT01774721

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Docetaxel

First Posted Date: 2012-12-24

Last Posted Date: 2012-12-24

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 60

Registration Number: NCT01755923

Locations: 🇨🇳
Department of Respiratory Medicine, Peking Union Medical College Hospita, Beijing, Beijing, China

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: gefitinib

First Posted Date: 2012-11-22

Last Posted Date: 2012-12-03

Lead Sponsor: Jiangmen Central Hospital

Target Recruit Count: 50

Registration Number: NCT01732276

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: INC280
Drug: Gefitinib

First Posted Date: 2012-06-04

Last Posted Date: 2021-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 161

Registration Number: NCT01610336

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Phase 1

Completed

Conditions: Solid Tumors
Lymphoma
Carcinoma, Non-Small-Cell Lung

Interventions: Biological: LY2875358
Drug: Erlotinib
Drug: Gefitinib

First Posted Date: 2012-05-18

Last Posted Date: 2015-06-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 17

Registration Number: NCT01602289

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan

Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR

Phase 2

Completed

Conditions: Stage IV Lung Cancer

Interventions: Drug: Gefitinib
Drug: Fulvestrant
Drug: Erlotinib

First Posted Date: 2012-03-16

Last Posted Date: 2021-01-08

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 379

Registration Number: NCT01556191

Locations: 🇫🇷
Clinique de l'Europe, Amiens, France
🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷
Hôpital Européen Georges Pompidou, Paris, France

and more 56 locations

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Gefitinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2012-03-05

Last Posted Date: 2020-09-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 265

Registration Number: NCT01544179

Locations: 🇨🇳
Research Site, Taipei, Taiwan

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Olaparib

First Posted Date: 2012-01-20

Last Posted Date: 2024-06-28

Lead Sponsor: Spanish Lung Cancer Group

Target Recruit Count: 186

Registration Number: NCT01513174

Locations: 🇪🇸
ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
H. Teresa Herrera, La Coruña, Spain
🇪🇸
H. Germans Trias i Pujol, Badalona, Barcelona, Spain

and more 2 locations

First Line Gefitinib by FDG-PET Metabolic Response

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2012-01-18

Last Posted Date: 2013-01-29

Lead Sponsor: Asan Medical Center

Target Recruit Count: 60

Registration Number: NCT01510990

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Phase 2

Conditions: Non Small Cell Lung Cancer
Adenocarcinoma

Interventions: Drug: Placebo
Drug: Gefitinib
Drug: Pemetrexed plusCIsplatin

First Posted Date: 2011-12-30

Last Posted Date: 2012-06-20

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 162

Registration Number: NCT01502202

Locations: 🇰🇷
National Cancer Center, Goyang-si, Gyenggido, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy